Latest Headlines

  1. Modernizing mRNA Quality Control 5/20/2026

    Oxford Nanopore Technologies, a company delivering a new generation of nanopore-based molecular sensing technology, and Lonza today announced the launch of a new technology approach designed to modernize and accelerate GMP quality control testing for mRNA therapeutics.

  2. AGC Biologics Joins Orphan Therapeutics Accelerator's Clinical Development Network As A Manufacturing Partner To Advance Cell And Gene Therapies For Ultra-Rare Diseases 5/14/2026

    Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling commercial access to stalled rare disease treatments, today announced that AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has joined OTXL’s Clinical Development Network (Orphan ClinDevNet) as a manufacturing partner.

  3. Aldevron And Minaris Renew Lentiviral Plasmid Agreement 5/14/2026

    FARGO, N.D. & PHILADELPHIA–(BUSINESS WIRE)–Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider today announced a renewed licensing agreement that expands access to a proprietary, off-the-shelf lentiviral plasmid system for gene-modified cell therapy applications.

  4. Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery 5/12/2026

    Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.

  5. 3PBIOVIAN Strengthens Its End-To-End CDMO Offering With State-Of-The-Art Sterility Testing, From Clinical To Commercial 5/7/2026

    3PBIOVIAN has significantly strengthened its sterility testing capabilities, reinforcing its position as an integrated, end-to-end CDMO serving biopharma customers from early development through commercial supply.

  6. Notes From The Road: INTERPHEX 2026 5/7/2026
  7. Made Scientific And RoosterBio Announce Strategic Technology And Supply Partnership To Expand Scalable MSC And Extracellular Vesicle Manufacturing 5/5/2026

    Partnership integrates RoosterBio's mesenchymal stem cell and extracellular vesicle platforms into Made Scientific's end-to-end CDMO capabilities to accelerate development and commercial-scale production of advanced therapies.

  8. AES Cleanroom Technology appoints John Groth As Chief Revenue Officer 4/27/2026

    AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, has appointed John Groth as Chief Revenue Officer as demand grows for flexible, high-performance manufacturing environments across pharma and biotech.

  9. Contec, Inc.® Partners With i-team Global To Deliver Cleanroom-Certified, Battery-Powered Mechanized Cleaning System 4/24/2026
  10. Minaris Delivers 100% Manufacturing And Release Success For Chimeric Therapeutics' CDH17 Autologous CAR‑T Program 4/23/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, “Chimeric” or the “Company”), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics’ CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as well as neuroendocrine cancers.